Volume 4, Issue 3, September 2020, Page: 104-110
Metabolic Syndrome in HIV/AIDS Patients at the Tiko Central Clinic and Cottage Hospital in Cameroon: Influence on Cardiovascular Risk and Predictors
Njeodo Njongang Vigny, Department of Medical Laboratory Sciences, University of Buea, Buea, Cameroon; Department of Medical Laboratory Sciences, Maflekumen Higher Institute of Health Sciences Tiko, Tiko, Cameroon
Jules Clement Nguedia Assob, Department of Medical Laboratory Sciences, University of Buea, Buea, Cameroon; Department of Biomedical Sciences, University of Buea, Buea, Cameroon
Achidi Eric Akum, Department of Biochemistry and Molecular Biology, University of Buea, Buea, Cameroon
Received: Jun. 27, 2020;       Accepted: Jul. 7, 2020;       Published: Jul. 17, 2020
DOI: 10.11648/j.ccr.20200403.15      View  154      Downloads  85
Highly active anti-retroviral therapy (HAART) use by HIV patients since the mid-1990’s has led to a significant drop in HIV mortality. However, HAART and HIV related metabolic syndrome (hypertriglyceridaemia, reduced HDL-c, abdominal obesity, hypertension, and insulin resistance) is associated with increased cardiovascular risk in aging HIV sero-positive patients. This study was aimed at investigating the predictors of metabolic syndrome and influence of metabolic syndrome on cardiovascular (CV) risk amongst persons living with HIV on HAART. This is a hospital-based case-control study. The cases were HIV sero-positive individuals on HAART for at least 6 months and controls were HIV sero-negative individuals. Out of 135 participants, 74 (54.8%) were females amongst which 53/75 (70.7%) were in the cases group and 21/60 (35%) were in the control group. The mean age of the participants was 42.04 (±9.61) years. HIV-infected participants at moderate CV risk based on the DAD risk calculator were more frequently diagnosed with metabolic syndrome based on the International Diabetes Federation (IDF) criteria with high statistical significance than those at low CV risk (5/19 – 26.3% vs. 12/55 – 21.8%, P=<0.001). Bivariate analysis of metabolic syndrome predictors in the study population revealed that gender is associated with increased odds of metabolic syndrome (OR: 5.376, 95% CI: 1.907-15.153; P=0.001). Gender was the only predictor associated with metabolic syndrome (OR: 6.958, CI: 2.317-20.896; P=0.001) following multivariate analysis of gender, vegetables or fruits intake, vigorous physical activity and family history of CVD and females were 7 times more likely to develop metabolic syndrome than males. More HAART-treated HIV patients at moderate CVD risk develop metabolic syndrome than those at low CVD risk. Female HIV patients on HAART have higher chances of developing metabolic syndrome compared to their male counterparts. HIV patients particularly females should be screened early for metabolic syndrome following HAART initiation.
Metabolic Syndrome, HIV, HAART, Cardiovascular Risk, Predictors
To cite this article
Njeodo Njongang Vigny, Jules Clement Nguedia Assob, Achidi Eric Akum, Metabolic Syndrome in HIV/AIDS Patients at the Tiko Central Clinic and Cottage Hospital in Cameroon: Influence on Cardiovascular Risk and Predictors, Cardiology and Cardiovascular Research. Vol. 4, No. 3, 2020, pp. 104-110. doi: 10.11648/j.ccr.20200403.15
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sabeena S, Justin RB, Sylvia O, Mina Q, Pascale W, Osaro M, et al. Metabolic Syndrome among people living with HIV receiving medical care in Southern United States: Prevalence and Risk factors. AIDS and Behavior 2019; 1-10.
Jules CNA, Vigny N, Vincent SV, John FT, Peter A, Eric AA. Evaluation of cardiovascular risk factors in HIV/AIDS patients attending the Tiko Central Clinic and Cottage hospital, Tiko, Cameroon. On J Cardiovas Res 2019; 2 (3): 1-7.
Sara P, Teresa R, Ana CM, Emilia V. Cardiovascular risk in HIV-infected individuals: A comparison of three risk prediction algorithms. Rev Port Cardiol 2019; 38 (7): 463-470.
Angelica CP, Miguel ASA, Sara GJ, Eduardo PM, German BF, Miguel CM, et al. Changes in cardiovascular risk and clinical outcomes in a HIV/AIDS cohort study over a 1-year period at a specialized clinic in Mexico. Therapeutics and Clinical Risk Management 2018; 14: 1757-1764.
Handan W, Alexandra C, Dianne LC, Katherine S, Andrew C, Matthew GL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21: 2445–2453.
Magdalena ES, Donald RH, Kathryn A, Kathleen M, Tianren T, Qiuhu Shi, et al. Prevalence and predictors of Metabolic Syndrome among HIV-Infected and HIV-Uninfected women in the women’s Interagency HIV Study. J Acquir Immune Defic Syndr 2008; 48 (3): 272-280.
Mohammadtaghi S, Seyed JM, Masoud M, Seyedeh MN, Mohammad HS, Ali P, et al. The Incidence of Metabolic Syndrome and the Most Powerful Components as Predictors of Metabolic Syndrome in Central Iran: A 10-Year Follow-Up in a Cohort Study. Iran Red Crescent Med J 2017 (7); 19: e14934.
Patrick DMCK, Friedrich T, Andre NHB, Tonya ME, Aime BM, Pierre PML, et al. Prevalence and risk factors of metabolic syndrome in HIV-infected adults at three urban clinics in a post-conflict setting, eastern Democratic Republic of the Congo. Tropical Medicine and International Health 2018; 23 (7): 795-805.
Olamide OT, Solange ZM, Benn S. Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa—a systematic review and meta-analysis. BMC 2019; 8 (4): 1-17.
Herbert AM, Henry DM, Anthony TK, Omarine N, Theresia NK. Prevalence of metabolic syndrome in human immunodeficiency virus - infected patients from the South-West region of Cameroon, using the adult treatment panel III criteria. Diabetol Metab Syndr 2014; 6 (92): 1-7.
UNAIDS. Cameroon: HIV/AIDS estimates. 2020. Available at: http://www.unaids.org/en/regionscountries/countries/Cameroon.
IDF. The IDF world consensus definition of the metabolic syndrome. 2006. Available at: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.
ClinRisk. Welcome to the QRISK®2-2016 risk calculator. 2016. Available at: https://qrisk.org.
HIV Pharmacovegilance. Risk Evaluation Tools. 2007. Available at: https://www.hivpv.org.
Elizabete SM, Marcela A, Christefany RBC, William S, Elucir G, Renata KR. Evaluation of cardiovascular risk factors in people living with HIV in São Paulo, Brazil. JIDC 2020; 14 (1): 89-96.
Clive RP, Bradley EA, Caryl G, Traci C, Irina M, Harvey D, et al. Metabolic Abnormalities and Coronary Heart Disease Risk in Human Immunodeficiency Virus–Infected Adults. METABOLIC SYNDROME AND RELATED DISORDERS 2010; 8 (3): 279-286.
Alvarez C, Salazar R, Galindez J, Rangel F, Castaneda ML, Lopardo G, et al. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis 2010; 14 (3): 256-263.
Mariana AR, Geyza NAA, Nathalia SG, Camila AC, Raissa DSS, Unai T. Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy. Rev Soc Bras Med Trop 2017; 50 (5): 598-606.
Catherine NK, Joyce NW, Elvis OO, Mark OO, Jane GM, Zeinab GR, et al. Prevalence and factors associated with metabolic syndrome in an urban population of adults living with HIV in Nairobi, Kenya. PAMJ 2018; 90 (90): 1-9.
Carlos G, Hernando K, Milagro M, Jordi OL, Ana G, Juan LG, et al. Metabolic Syndrome Among HIV-Infected Patients: Prevalence, characteristics, and related factors. Diabetes Care 2005; 28 (1): 132-137.
Dula DB, Lemessa D, Teshale AM, Dawit AA, Mikyas GT, Tesfahun CE. Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV). Diabetol Metab Syndr 2018 (10); 10: 1-9.
Gibson BK, Godfather DK, Clement NM, Andrew MK, Ray MM, Amani FS, et al. Prevalence and Risk Factors of Metabolic Syndrome among Individuals Living with HIV and Receiving Antiretroviral Treatment in Tanzania. BJMMR 2015; 5 (10): 1317-1327.
Oumar G, Herve T, Arnaud ED, Yempabou S, Ismael D, Bertille Y, et al. Features of Metabolic Syndrome and Its Associated Factors during Highly Active Antiretroviral Therapy in Ouagadougou (Burkina Faso). JIAPAC 2016; 15 (2): 159–163.
Alfred O, Tecla MT, Nicholas K, Edmond KN, Jemima HK, Stephanie P, et al. Metabolic Syndrome Among Antiretroviral Therapy-Naïve Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya. AIDS PATIENT CARE and STDs 2018; 32 (6): 215-222.
Basile GS, Nicodeme WC, Victorien TD, Esther D, Arnaud NK, Veronique BTT, et al. Prevalence of metabolic syndrome and associated risk factors in the population of Southern Benin. Int J Biosci 2019; 15 (5): 205-217.
Agete TH, Demo YT. Influences of gender in metabolic syndrome and its components among people living with HIV virus using antiretroviral treatment in Hawassa, southern Ethiopia. BMC Res Notes 2016; 9 (145): 1-7.
Eyitayo OO, Daniel TG, Oladele VA, Aanuoluwa OA, Eunice S. Prevalence and Correlates of Metabolic Syndrome Among Adults Attending Healthcare Facilities in Eastern Cape, South Africa. TOPHJ 2017; 10: 148-159.
Julia HC, Carol C, Yana V, John R, Margaret M, Peter B. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 1-12.
Magdalena RP, Anna G, Pawel R, Mariusz L, Robert F. Metabolic syndrome in HIV infected adults in Poland. Kardiol Pol 2018 (3); 76: 548-553.
Mark Mascolini. When and How to screen for cardiovascular disease risk in people with HIV. 2013. Available at: https://www.thebodypro.com.
Browse journals by subject